Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

Table 4 Clinical outcomes of patients(Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

Clinic outcomes	Group 1	Group 2	Group 3	p-value
ARDS	6^a (12.5%)	10^b (20.8%)	0^a,b (0.0%)	0.005^a 0.005^b
ICU	13^c (27.1%)	13^d (27.1%)	1^c,d (2.1%)	0.001^c 0.001^d
Intubation	2 (4.2%)	4 (8.3%)	0 (0.0%)	NS
Death	2 (4.2%)	4 (8.3%)	0 (0.0%)	NS

Statistically significant values are presented in bold. Superscript letters define the significant p-values of pairwise comparisons. Tukey's test and Games Howell tests were preferred as posthoc tests
ARDS acute respiratory distress syndrome; ICU ıntensive care unit
^a denotes the comparison of patients with ARDS in Group 1 vs. Group 3
^b denotes the comparison of patients with ARDS in Group 2 vs. Group 3
^c denotes the comparison of patients with ICU in Group 1 vs. Group 3
^d denotes the comparison of patients with ICU in Group 2 vs. Group 3

ISSN: 1743-422X